Sparks - Oryzon Genomics

Oryzon Genomics has announced that the United States Patent and Trademark Office (USPTO) has granted a patent relating to therapeutic combinations of iadademstat, covering its use in methods for treating neoplastic diseases, including acute myeloid leukaemia (AML). The patent should provide protection to January 2039, including 681 days of patent term adjustment granted by the USPTO to compensate for delays during patent prosecution. We note that this does not include any potential patent term extensions, which could further extend the duration of coverage.

In addition to the US, Oryzon has obtained patent protection for combinations of iadademstat with venetoclax, or their use in the treatment of cancer, in Australia, Brazil, Canada, Europe, India, Israel, Japan, Korea, Malaysia, Mexico, New Zealand and Russia. Further patent applications are pending in other key regions. The company also holds granted patents covering combinations of iadademstat with other AML therapies, including azacitidine and decitabine, in the US and other geographies.

This latest news is supportive of our updated investment thesis for Oryzon, details of which can be found in our recently published outlook note.